MIRAGEN THERAPEUTICS, INC. MGEN Income Statement

Miragen therapeutics, inc. (MGEN)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Sep'13	Jun'13
Collaboration revenue
-	-	-	-	-	-	-	-	-	-	-	-	1,907	2,814	0	0	0	-	-	-	-	-	-	-	-	-	-
Grant revenue
-	-	-	-	-	-	-	-	-	-	-	-	1,115	663	0	0	0	-	-	-	-	-	-	-	-	-	-
Revenue:
Total revenue
4,917	4,461	4,057	4,306	3,974	8,386	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total revenue
-	-	-	-	-	-	-	-	-	-	-	-	3,022	3,477	3,626	3,191	2,810	2,538	2,534	3,334	3,874	4,320	4,649	4,451	0	0	0
Operating expenses:
Cost of revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,472	2,796	3,119	3,395	3,366	3,298	3,001	0	0	0
Research and development
32,146	34,794	34,611	32,983	32,759	30,421	27,185	24,804	21,916	19,623	18,531	16,478	14,346	13,692	10,241	7,529	4,368	1,002	626	478	412	347	314	232	0	0	0
Selling and marketing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,559	2,220	1,593	1,085	717	400	298	0	0	0
General and administrative
11,012	11,646	11,807	11,605	11,416	11,049	10,902	10,708	10,621	10,912	10,881	10,432	9,061	6,772	6,203	6,153	6,721	7,692	7,478	7,235	8,394	6,857	5,558	4,268	0	0	0
Total operating expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Total operating expenses
43,158	46,440	46,418	44,588	44,175	41,470	38,087	35,512	32,537	30,535	29,412	26,910	23,407	20,464	0	0	0	-	-	0	0	-	9,572	7,801	0	0	0
Loss from operations
-38,241	-41,979	-42,361	-40,282	-40,201	-33,084	-28,985	-25,723	-24,212	-26,532	-26,092	-24,285	-20,385	-16,987	-14,030	-13,076	-12,116	-11,187	-10,486	-8,991	-9,312	-6,867	-4,922	-3,350	0	0	0
Other income (expense):
Interest and other income
697	941	1,182	1,340	1,426	1,254	1,048	799	540	403	261	155	62	39	0	0	0	-	-	-	-	-	-	-	-	-	-
Interest and other expense
744	835	893	911	896	873	835	671	521	383	269	289	308	326	0	0	0	-	-	-	-	-	-	-	-	-	-
Interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	141	120	100	506	1,023	1,588	2,064	0	0	0
Net Income (Loss) Attributable to Parent
-38,288	-41,873	-42,072	-39,853	-39,671	-32,703	-28,772	-25,595	-24,193	-26,512	-26,100	-24,419	-20,631	-17,274	-14,280	-13,279	-12,317	-11,328	-10,606	-9,091	-9,818	-7,890	-6,571	-5,564	0	0	0
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax
-2	3	9	7	2	-3	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss
-38,290	-41,870	-42,063	-39,846	-39,669	-32,706	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of redeemable convertible preferred stock to redemption value
-	-	-	-	-	-	-	-	-	5	41	54	66	49	0	0	0	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Dividend to member unit holder of Myeloma Health LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Net loss
-38,288	-41,873	-42,072	-39,853	-39,671	-32,703	-28,772	-25,595	-24,193	-26,517	-26,117	-24,449	-20,673	-17,323	0	0	0	-	-	-	-	-	-	-	-	-	-
Net loss per share, basic and diluted (in dollars per share)
-0.18	-0.31	-0.36	-0.29	-0.38	-0.34	-0.29	-0.29	-0.18	-0.17	-0.27	-0.34	-0.60	-9.83	-6.92	-5.88	-5.58	-14.39	-5.85	-0.33	-0.45	-43.84	-0.40	-4.73	-3.53	-0.35	-0.24
Weighted-average shares used to compute basic and diluted net loss per share (in shares)
45,476	32,394	31,081	30,983	30,886	30,899	30,723	30,295	26,483	22,440	21,572	21,409	11,555	601	601	601	651	-11,962	541	7,785	5,793	-4,356	4,062	695	200	2,672	2,591
Collaboration revenue
Total revenue
4,641	4,308	3,906	4,095	2,965	7,373	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant revenue
Total revenue
276	153	151	211	1,009	1,013	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-